Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 2/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.65 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 12/20 | 0.50 |
| ▸ | HTR7 | P34969 | 12/20 | 0.50 |
| ▸ | HTR1D | P28221 | 3/20 | 0.49 |
| ▸ | HTR1B | P28222 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5361640 | 1.00 | CHRM3 (0.67) | CHRM3CHRM2CHRM1DRD2DRD4 | |
| SCHEMBL9759621 | 0.84 | DRD2 (0.49) | CHRM3CHRM2CHRM1DRD2DRD4 | |
| SCHEMBL9759874 | 0.83 | DRD2 (0.58) | DRD2DRD4DRD3HTR1AHTR7 | |
| SCHEMBL14591348 | 0.82 | CHRM3 (0.47) | CHRM3CHRM2CHRM1 | |
| SCHEMBL14591308 | 0.81 | CHRM3 (0.69) | CHRM3CHRM2CHRM1DRD2DRD4 | |
| SCHEMBL8630151 | 0.80 | HTR1A (0.71) | DRD2DRD3HTR1AHTR7HTR1D | |
| SCHEMBL7763389 | 0.80 | HTR1A (0.71) | DRD2DRD3HTR1AHTR7HTR1D | |
| SCHEMBL8634782 | 0.80 | HTR1A (0.71) | DRD2DRD3HTR1AHTR7HTR1D | |
| SCHEMBL8891132 | 0.80 | CHRM3 (1.00) | CHRM3CHRM2CHRM1DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL6542162 | 0.80 | CHRM3 (0.67) | CHRM3CHRM2CHRM1DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1052982-A4 | AMINOTETRALINS AS 5-HT 1D$g(a)? AGONISTS | LILLY CO ELI (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20020065312-A1 | Aminotetralins as 5-HT1Dalpha agonists | SCHAUS JOHN M (US) | 2002-05-30 | — | — | US | disclosed |
| US-6355674-B1 | PSYCHOLOGICAL DISORDERS; ANTISEROTONINE AGENTS | ELI LILLY AND COMPANY | 2002-03-12 | — | — | US | disclosed |
| EP-1052982-A1 | AMINOTETRALINS AS 5-HT 1D$g(a)? AGONISTS | ELI LILLY AND COMPANY (US) | 2000-11-22 | — | — | EP | disclosed |
| WO-1998048786-A1 | AMINOTETRALINS AS 5-HT1Dα AGONISTS | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065312-A1 | Aminotetralins as 5-HT1Dalpha agonists | HTR1D, HTR1A, HTR1E | CHRM3 754/4885CHRM2 1303/4885CHRM1 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.